Skip to content
Open access

Risk factors of atrial arrhythmia recurrence and impact on the benefit of oral anticoagulation discontinuation: insights from the ALONE-AF trial

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

The significant interaction between recurrence-risk strata and OAC strategy supports tailored anticoagulation strategies guided by an individual’s recurrence risk profile.

Abstract

In the ALONE-AF trial, discontinuation of oral anticoagulation (OAC) reduced the risk of the primary outcome (a composite of stroke, systemic embolism, and major bleeding) in patients without atrial arrhythmia recurrence after catheter ablation for atrial fibrillation (AF). This post-hoc analysis aimed to identify risk factors for atrial arrhythmia recurrence after catheter ablation and to evaluate whether the effect of OAC discontinuation varied according to recurrence risk. We randomized patients with AF to continue or discontinue OAC and followed them for ≥2 years. The risk factors associated with atrial arrhythmia recurrence at 2 years were identified using Cox regression models based on backward elimination. We evaluated the 2-year cumulative incidence of the primary outcome using the Kaplan–Meier method and assessed the interaction between recurrence risk and OAC strategy. Overall, 840 patients (mean age 64.1±8.1 years, 24.9% female) were included. Atrial arrhythmia recurrence was documented in 77 patients and was independently associated with female sex (HR, 2.31 [95% CI, 1.37–3.91]), heart failure (HR, 2.37 [95% CI, 1.35–4.17]), and left atrial enlargement (HR, 1.82 [95% CI, 1.08–3.05]). Among the 231 patients without risk factors, the risk of the primary outcome was significantly higher in patients who continued OAC than in those who discontinued OAC (absolute difference, 5.5% points [95% CI, 1.2–9.7]). Among the 568 patients with ≥1 risk factors, the differences were not prominent (absolute difference, 0.4% points [95% CI, −1.0–1.9]; p for interaction=0.028). Female sex, heart failure, and left atrial enlargement were identified as risk factors for atrial arrhythmia recurrence. The significant interaction between recurrence-risk strata and OAC strategy supports tailored anticoagulation strategies guided by an individual’s recurrence risk profile.Graphical abstractStudy population

Read PDF

Similar papers

Oct 2026

Stroke Risk-Based Anticoagulation After Atrial Fibrillation Ablation: ALONE-AF Post-Hoc Analysis.

BACKGROUND Discontinuation of oral anticoagulant (OAC) in patients without recurrent atrial arrhythmia after ablation for atrial fibrillation (AF) has been demonstrated to reduce composite outcomes of stroke, systemic embolism, and major bleeding compared with continued OAC. OBJECTIVE This study aimed to evaluate the...

Young-Shin Lee, J. Uhm, Junbeom Park et al. · 0 citations
Nov 2026

Abstract 7621: Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation: A Meta-Analysis of Randomized Controlled Trials

Background: The optimal strategy for long-term oral anticoagulation (OAC) after catheter ablation for atrial fibrillation (AF) remains uncertain. Although current guidelines recommend anticoagulation based on thromboembolic risk scores irrespective of rhythm status, this recommendation has not been validated by rand...

A. Karthikeyan, Maisha Maliha, Adir Alper et al. · 0 citations
Review Nov 2026

Cessation of oral anticoagulation after atrial fibrillation ablation: who and when?

For patients without high-risk features for thromboembolism, the OCEAN and ALONE-AF trials showed that OAC cessation is a viable option at 1 year after ablation if no atrial fibrillation is documented by routine rhythm monitoring modalities.

J. Lee, A. Verma, D. Birnie et al. · 0 citations
Oct 2026

Clinical impact of early recurrence of atrial fibrillation after catheter ablation on subsequent ischemic stroke: STOP-OAC study

Regarding oral anticoagulation therapy after catheter ablation for atrial fibrillation (AF), the European Society of Cardiology guidelines recommend continuing oral anticoagulation after AF ablation according to the patient’s CHA2DS2-VA score (Class I). The Japanese Circulation Society guidelines provide a Class...

A. Suenaga, K. Kujira, A. Morinaga et al. · 0 citations
Review Oct 2026

Role of Lifestyle and Risk Factor Modification Clinics in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

BACKGROUND Incidence and recurrence of atrial fibrillation (AF) are associated with several lifestyle risk factors. Lifestyle and risk factor modification (LRFM) clinics could have a role in comprehensively addressing AF from a holistic, patient-centered approach to improve clinical outcomes. METHODS We performed a s...

Yan Zhao, F. Ha, Adam J. Brown et al. · 0 citations
Review Open access Nov 2026

Oral anticoagulation with or without antiplatelet therapy for secondary stroke prevention in patients with atrial fibrillation and atherosclerosis: a systematic review and meta-analysis.

Patients with ischemic stroke (IS), atrial fibrillation (AF), and atherosclerosis have an increased risk of recurrent ischemic events. Addition of antiplatelet therapy (APT) to oral anticoagulant therapy (OAC) may offer additional protection against these events, at the cost of an increased risk of bleeding. This syste...

Victor Hugo Pinheiro Lopes, A. M. Pereira da Silva, L. Cardoso et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.